% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • efficient_frontier2002 efficient_frontier2002 Sep 30, 2012 12:02 AM Flag

    6mo N=108 HR=.37 p=0.01 AND no-smoke N=130 HR=.48 p=0.02

    There's a lot more that's good that can be said about the GALAXY trial, ganetespib and Synta, but it seems to me that this information is all we really need. Well done Synta!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For a graph of these numbers, see slide 20 of the ESMO presentation. A picture is worth a thousand words.

      In the case of the 6 months since diagnosis group, the D+G has had only 7 deaths compared to 18 deaths in the D group, resulting in a Kaplan-Meier overall survival @ 11 months of .71 for D+G compared to .26 for D (p=0.010).

      Synta has the option of restricting Phase 3 to this population. My guess is it will.

      I don't think anybody was expecting these hugely advantageous exclusion opportumities (including the one in Slide 31 which I forgot to mention), only one of which results in a strongly statistically significant p of 0.010. The p will only get better (lower) with a larger Phase 3 N of around 500 and perhaps more restrictions.

      This is extremely good news that I doubt anybody was expecting.

      Sentiment: Strong Buy

0.343+0.072(+26.61%)Jul 22 4:00 PMEDT